Check out these key findings about Organon & Co. (OGN)

With 2.14 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.36 million shares. During the session, the Drug Manufacturers – General company that operates in wider Healthcare sector, reached to the highest price of $21.56 whereas the lowest price it dropped to was $21.135. The 52-week range on OGN shows that it touched its highest point at $24.08 and its lowest point at $10.84 during that stretch. It currently has a 1-year price target of $22.50. With its current market cap of 5.49 billion, OGN has annualized dividend of $1.12 while the current yield stands at 5.25%. Beta for the stock currently stands at 0.81.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of OGN was up-trending over the past week, with a rise of 4.66%, but this was up by 20.55% over a month. Three-month performance surged to 32.44% while six-month performance rose 92.00%. The stock gained 2.30% in the past year, while it has gained 48.06% so far this year. A look at the trailing 12-month EPS for OGN yields 4.08 with Next year EPS estimates of 4.58. For the next quarter, that number is 1.17. This implies an EPS growth rate of 7.07% for this year and 3.44% for next year. EPS is expected to grow by 2.90% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -14.04%.

Float and Shares Shorts:

At present, 257.17 million OGN shares are outstanding with a float of 256.66 million shares on hand for trading. On 2024-04-30, short shares totaled 12.09 million, which was 470.0 higher than short shares on 1711584000. In addition to Mr. Kevin Ali as the firm’s CEO & Director, Mr. Matthew M. Walsh serves as its Executive VP & CFO.

Institutional Ownership:

Through their ownership of 0.8049 of OGN’s outstanding shares, institutional investors have minority control over the company.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-03-31, OGN reported revenue of $1622000000.0 and operating income of $414000000.0. The EBITDA in the recently reported quarter was $476000000.0 and diluted EPS was $0.78.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for OGN since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.